Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment

Area of Science:

• Genetics and Cardiovascular Medicine
• Rare Disease Pathophysiology
• Lipid Metabolism Disorders

Background:

• Homozygous familial hypercholesterolemia (HoFH) is a severe autosomal co-dominant disease caused by mutations in the LDLR gene.
• Mutations in PCSK9, APOB, and ARH genes can also lead to HoFH-like phenotypes with varying severity.
• HoFH is characterized by severe defects in the low-density lipoprotein receptor (LDLR), leading to excessive atherogenic lipoproteins.

Purpose of the Study:

• To provide current perspectives on the diagnosis and therapy of Homozygous Familial Hypercholesterolemia (HoFH).
• To encourage early recognition and prompt treatment of this rare but severe genetic disease.
• To highlight the aggressive cardiovascular disease and unique clinical manifestations in HoFH patients.

Main Methods:

• Review of current literature on HoFH diagnosis and treatment.
• Analysis of genetic mutations associated with HoFH and related phenotypes.
• Evaluation of current and emerging therapeutic strategies for managing HoFH.

Main Results:

• HoFH presents with exceptionally high LDL cholesterol levels, xanthomas, and stenosis from early life.
• Accelerated atherosclerosis and cardiovascular disease are hallmarks of HoFH, often manifesting within the first two decades.
• Current treatments include lipid-modifying therapy and LDL apheresis, with statins improving survival.

Conclusions:

• Early identification and intervention are critical for improving outcomes in HoFH patients.
• Ongoing research into novel therapeutics offers hope for enhanced survival and quality of life.
• A comprehensive understanding of HoFH diagnosis and management is essential for clinicians.